Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05769348 · ClinicalTrials.gov registry record · NA
Investigation and Modulation of the Central Mu-Opioid Mechanism in Migraine (in Vivo)
A NA study of Chronic Migraine, sponsored by University of Michigan.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05769348: Recruiting NA study of Chronic Migraine, sponsored by University of Michigan.
NCT05769348 is a NA study of Chronic Migraine that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 80 participants, below the 339-participant average among 17 other Chronic Migraine trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05769348, a NA study of Chronic Migraine, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study investigates whether unilateral and bilateral non-invasive brain stimulation, given for 20 minutes/once per day for twenty days (M-F) can reduce migraine pain. Fourty patients will receive treatment (20 unilateral treatment, and 20 bilateral treatment), while twenty will receive a "sham" procedure. Another 20 Episodic Migraine patients will be recruited for the observational aim of the study which does not include brain stimulation.
Primary Outcome
Headache Day: day with a headache that causes moderate or severe pain (at its peak, defined as NRS ≥ 4) that lasts at least 4 hours, OR day with a headache that is treated by an acute headache medication.
Conditions Studied
Interventions
- DEVICE HD-tDCS Active Protocol
- DEVICE HD-tDCS Sham Protocol
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-01-26 |
| Est. Completion | 2026-12-30 |
| Phase | NA |
What NCT05769348 shows while recruiting
NCT05769348 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 339-participant average among 17 other Chronic Migraine trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Chronic Migraine appearing as the primary indexed condition, and to 2 interventions - of which HD-tDCS Active Protocol is the first listed.
NCT05769348 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05769348 about?
NCT05769348 is a clinical study titled "Investigation and Modulation of the Central Mu-Opioid Mechanism in Migraine (in Vivo)". This study investigates whether unilateral and bilateral non-invasive brain stimulation, given for 20 minutes/once per day for twenty days (M-F) can reduce migraine pain. Fourty patients will receive treatment (20 unilateral treatment, and 20 bilateral treatment), while twenty will receive a "sham" ...
What is the current status of trial NCT05769348?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2023-01-26. Estimated completion is 2026-12-30.
What conditions does trial NCT05769348 study?
This clinical trial studies the following conditions: Chronic Migraine.
What interventions are being tested in trial NCT05769348?
The interventions under investigation include: HD-tDCS Active Protocol (DEVICE), HD-tDCS Sham Protocol (DEVICE).
Who is sponsoring clinical trial NCT05769348?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05769348 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05769348's enrollment target sits among peer trials
80 12th of 17 higher than 6 of 17 other Chronic Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
-
Acceptance and Commitment Therapy to Improve Disability in Chronic Migraine
RECRUITING · NA
-
Mind Body Balance for Pediatric Migraine
RECRUITING · NA
-
Brief Interventions in Chronic Migraine
ACTIVE NOT RECRUITING · NA
-
Efficacy of Behavioral Insomnia Treatment for Chronic Migraine
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI